Introduction {#sec1}
============

Anaplastic large-cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that was first identified by Stein *et al*. in 1985 as a neoplastic entity of large cells with abundant cytoplasm and kidney-shaped nuclei. ALCL affects both nodal and extra nodal sites and constitutes \~15% of pediatric NHL \[[@ref1]\].

Systemic ALCL is the most common type and mostly affects men \[[@ref2]\]. It's categorized into two main subtypes according to the expression of a protein called anaplastic large-cell kinase (ALK): ALK-positive ALCL which is more common in young adults, while ALK-negative ALCL tends to affect older males with a worse prognosis \[[@ref2], [@ref3]\].

Herein, we report a rare case of a 13-year-old girl who was diagnosed with an ALK-negative ALCL in the mediastinum with regards to pathological and immunohistochemical features of this neoplasm.

CASE REPORT {#sec2}
-----------

We report a case of a 13-year-old Syrian girl who was admitted to the hospital on 16/7/2018 due to dysphagia, dyspnea, edema in the face, pallor and asthenia. Clinical examination revealed large masses in the mediastinum causing symptoms of superior vena cava syndrome. Blood examination showed WBC count 6 × 10^9^/L, lymphocyte count 48%, neutrophil count 42%, hemoglobin count 85 g/L and CRP 117.

Chest radiography revealed an abnormal shadow in the mediastinum extending to pulmonary hilar region (Fig. [1](#f1){ref-type="fig"}). Furthermore, CT scan demonstrated large masses in the anterior mediastinum (Fig. [2](#f2){ref-type="fig"}) with no other masses elsewhere. Thus, our patient underwent surgery on 30 July 2018 for complete resection of the mediastinal lesions to remove the symptoms. Gross examination revealed that the resected masses were 10 enlarged Lymph nodes measuring 3--7 cm. Microscopic examination revealed cohesive sheets of diffuse large pleomorphic cells effacing the nodes architecture (Fig. [3A and B](#f3){ref-type="fig"}), characterized by abundant cytoplasm and kidney-shaped nuclei with abnormal mitotic figures and Reed--Sternberg-like cells (Fig. [3C and D](#f3){ref-type="fig"}). Thus, differential diagnosis included ALCL, classical Hodgkin lymphoma (CHL), peripheral T-Cell lymphoma and diffuse large B-cell lymphoma (DLBCL).

![A chest radiography demonstrates an abnormal shadow in the mediastinum extending to the pulmonary hilar region.](omz077f1){#f1}

![CT scan of the upper thoracic region demonstrate enlarged lymph nodes (Black Arrows) in the anterior mediastinum.](omz077f2){#f2}

![H&E sections of resected lymph nodes demonstrating: (A and B) cohesive sheets of diffuse pleomorphic cells effacing the nodes architecture; (C and D) neoplastic cells characterized by abundant cytoplasm and kidney-shaped nuclei with multiple abnormal mitotic figures in addition to Reed--Sternberg like cells](omz077f3){#f3}

Immunohistochemical stainings showed strong CD30 positivity for large and Reed--Sternberg-like cells ([Fig. 4](#f4){ref-type="fig"}A and B), whereas CD15, CD3, CD20, ALK, CD45Ro and EMA were negative ([Figs 4 and 5](#f5){ref-type="fig"}). These results confirmed the diagnosis of ALK--ALCL.

![Immunohistochemistry of the lymph nodes: (A and B) strong CD30 positivity for large and Reed--Sternberg-like cells; (C) negativity for CD20; (D) negativity for ALK.](omz077f4){#f4}

![Immunohistochemistry of the lymph nodes: (A) CD15 is negative; (B) CD45Ro is negative; (C) CD3 is negative; (D) EMA is negative.](omz077f5){#f5}

The patient received chemotherapy based on NHL-BFM 90 Protocol for ALCL. Thus treatment regimen was based on alternating courses that included dexamethasone, cyclophosphamide, methotrexate, cytarabine, vincristine, etoposide, doxorubicin, ifosfamide and prednisolone.

The last chest and abdomen CT scan on 18 March 2019 showed complete response and the patient is currently in remission on maintenance therapy of Vinblastine 10 mg/m^2^.

Discussion {#sec3}
==========

ALCL is an aggressive rare type of non-Hodgkin lymphoma that's characterized by pleomorphic cells labeled by Ki-1 antibody \[[@ref4]\]. It constitutes nearly 15% of pediatric NHL and 2% of all NHL. Furthermore, about 15--20% of ALCL cases affect patients under 20 years old mostly males \[[@ref4], [@ref5]\], our rare case, however, was described in a 13-year-old female.

According to the revised fourth edition of the WHO classification (2017), ALCL is defined as a CD30-positive neoplasm of T or null cell lineage, as these tumors are distinguished by their anaplastic cytology and constant membrane expression of CD30 antigen \[[@ref5], [@ref6]\].

There are two subsets of ALCL: Primary cutaneous ALCL which is confined to the skin, and Systemic ALCL that affects all organs mostly the lymph nodes, with involvement of extra nodal sites including bone marrow, skin, soft tissues, lung and liver \[[@ref2]\]. The mediastinum is involved in \~10% \[[@ref7]\], and as it is a common site in CHL, we have faced more challenges adding CHL to differential diagnosis.

Furthermore, systemic ALCL is categorized into two main subtypes according to the expression of a protein called ALK: ALK-positive ALCL which constitutes 50--80% and is more common in young adults with a survival rate of 70--90% for 5 years, while ALK-negative ALCL represents 20--50% and tends to affect older adults with a worse prognosis and a survival rate of 40--60%. Male predominance (60%) is seen in both subtypes \[[@ref8], [@ref9]\].

Diagnosing ALCL can be challenging. Cytomorphologic findings, immunohistochemistry and clinical data were critical as there are certain similarities between ALCL, Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and DLBCL. These features include the proliferation of large pleomorphic cells with abundant cytoplasm and large atypical nuclei. And this gives an essential role for immunohistochemistry \[[@ref9], [@ref10]\].

Morphologically in ALCL, we see cohesive sheets of large pleomorphic cells with abundant cytoplasm and kidney-shaped nuclei surrounded by an inflammatory background \[[@ref10]\]. Neoplastic cells resemble Reed-Sternberg cells raising the difficulty in differentiating it from CHL.

However, CHL lacks cohesive growth pattern and has classical Reed--Sternberg cells with an inflammatory background and band-like fibrosis. Likewise, DLBCL can be distinguished with its large B-cells lineage, while PTCL-NOS is recognized with small clusters of epithelioid histiocytes resembling granulomas \[[@ref8], [@ref10]\].

In addition, IHC stainings for ALK, CD30, CD3, CD15, CD20, CD45Ro and EMA are valuable in the differential diagnosis. In ALK--ALCL, cells show strong positivity for CD30, usually in Golgi region and at the cell membrane. Our case also showed negativity for CD15 excluding CHL. Without forgetting negativity for CD20 and EMA excluding DLBCL and negativity for CD3 and CD15 excluding PTCL-NOS.

Molecularly, detecting ALK protein correlates with a chromosomal translocation that involves NPM gene on chromosome 5q35 and ALK gene on chromosome 2p23. Furthermore, ALK+ALCL is characterized by overexpression of HIF1-a target genes as well as interleukin10 and H-ras/K-ras induced genes, while ALK--ALCL is enriched for TMOD1, TNFRSF8, GATA3, MYC, IRF4 target genes and PI3K pathway-regulated genes. Studies also revealed that DUSP22 and P63 rearrangement were present in 30% and 8% of ALK--ALCL cases respectively, but absent in ALK+ALCL \[[@ref10]\]. Nevertheless, molecular testing has been largely replaced by immunohistochemistry. In addition, these tests were not available in our country, thus the diagnosis was based on immunohistochemical and cytomorphologic findings.

Furthermore, although studies showed correlation between the presence of ALK/Ki1 antigen and young ages, our case was ALK-negative presenting in a 13-year-old patient.

In conclusion, diagnosing ALK--ALCL represented a hard challenge due to rarity of presenting in young ages, male predominance and difficulties in diagnosis. However, with proper immunohistochemical stainings and detailed cytomorphologic observation, diagnosis was confirmed in our case.
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